Boulevard Bio is paying $20 million upfront to acquire global rights to a trispecific T-cell engager for autoimmune diseases from Metis TechBio, with potential payments totaling up to $1.6 billion plus tiered royalties. The preclinical program, MTS-128, was developed on Metis’ NanoForge platform and is designed to engage three targets simultaneously, aiming to expand selectivity and improve therapeutic window relative to traditional bispecific TCEs. The agreement reflects continued investor and pharma interest in multi-specific TCE architectures as companies push beyond single- and dual-target engagement. Metis, founded by former Kala Pharmaceuticals leadership and MIT scientists, recently went public and says it owns a proprietary lipid library underpinning its delivery work. For Boulevard, the deal adds early-stage differentiation in immune-cell redirecting modalities; for Metis, it validates external commercialization pathways for preclinical programs built on AI-assisted design.